ABC | Volume 112, Nº2, February 2019

Original Article Somuncu et al Antiplatelet resistance in young MI patients Arq Bras Cardiol. 2019; 112(2):138-146 Figure 1 – Bar graph showing major cardiovascular adverse events, in the four groups based on aspirin and clopidogrel response. (A) Patients with adequate response to dual antiplatelet therapy; (B) patients with low response to aspirin; (C) patients with low response to clopidogrel; (D) patients with low response to dual antiplatelet therapy. MACE: major adverse cardiovascular events. ¶ compared with poor responders to dual antiplatelet therapy (OR:1.875 1.144-3.073, p < 0.001); ‡ compared with patients with poor response to clopidogrel (OR: 1.198, 0.957-1.499, p = 0.036). 100.00 80.00 60.00 40.00 20.00 Presence % 0.00 MACE + 6.3 ¶‡ 15 21.7 50 3 year follow-up results A B C D Table 3 – Multivariate logistic regression analysis for potential predictors of major adverse carediovascular events (MACE) at three-year follow-up Univariate analysis Multivariate analysis OR (95%CI) p value OR (95%CI) p-value First Model ¶ Age, years 1.079 (0.951- 1.225) 0.239 Male 2.420 (0.569-10.292) 0.231 Family history 5.056 (1.720-14.861) 0.003 5.972 (1.449-24.615) 0.013 Hyperlipidemia 1.142 (0.435-2.994) 0.788 Diabetes mellitus 3.481 (1.026-11.810) 0.045 5.194 (0.884-30.540) 0.068 Hypertension 2.323 (0.878-6.142) 0.089 3.271 (0.823-12.998) 0.092 Culprit artery* 4.583 (1.434-14.650) 0.010 2.959 (0.604–14.498) 0.181 LVEF, % 0.878 (0.823-0.938) < 0.001 0.832 (0.761-0.909) < 0.001 Creatinine, mg/dl 0.828 (0.051-13.450) 0.894 Asp agg. time (AU x min) 1.002 (1.000-1.003) 0.078 1.000 (0.998-1.003) 0.838 Clop agg time (Au x min) 1.002 (1.000-1.004) 0.041 1.003 (1.000-1.006) 0.022 Second Model † Responder ‡ Ref. Ref. Ref. Ref. Asp res ‡ 2.647 (0.539-12.992) 0.230 2.075 (0.503-8.549) 0.312 Clop res ‡ 4.167 (1.011-17.175) 0.048 4.056 (0.618 -25.612) 0.065 Dual res ‡ 15.000 (3.666-61.366) <0.001 3.334 (0.484-22.954) 0.002 CI: confidence interval; LVEF: left ventricular ejection fraction; Asp: aspirin; Clop: Clopidogrel; agg: aggregation; min: minute; AU: aggregation unit; res: resistant; MACE: major adverse cardiovascular events; OR: odds ratio. *Culprit artery was divided as left anterior descending artery (LAD) and non-LAD (circumflex artery and right coronary artery); ‡ These groups were included in a second model instead of aspirin and clopidogrel aggregation time; ¶ Nagelkerke R square of the first model was 49.2%; † Nagelkerke R square of the second model was 59.4%. 142